PL377823A1 - Kompozycje farmaceutyczne - Google Patents

Kompozycje farmaceutyczne

Info

Publication number
PL377823A1
PL377823A1 PL377823A PL37782304A PL377823A1 PL 377823 A1 PL377823 A1 PL 377823A1 PL 377823 A PL377823 A PL 377823A PL 37782304 A PL37782304 A PL 37782304A PL 377823 A1 PL377823 A1 PL 377823A1
Authority
PL
Poland
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
PL377823A
Other languages
English (en)
Other versions
PL212950B1 (pl
Inventor
Jonathan David Castile
Peter James Watts
William Columbus Ian Lafferty
Alan Smith
Original Assignee
Archimedes Development Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9950919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL377823(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Archimedes Development Limited filed Critical Archimedes Development Limited
Publication of PL377823A1 publication Critical patent/PL377823A1/pl
Publication of PL212950B1 publication Critical patent/PL212950B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
PL377823A 2003-01-10 2004-01-12 Kompozycja do donosowego podawania fentanylu, zastosowanie farmaceutycznie dopuszczalnej substancji pomocniczej oraz sposób wytwarzania kompozycji PL212950B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0300531.1A GB0300531D0 (en) 2003-01-10 2003-01-10 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
PL377823A1 true PL377823A1 (pl) 2006-02-20
PL212950B1 PL212950B1 (pl) 2012-12-31

Family

ID=9950919

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377823A PL212950B1 (pl) 2003-01-10 2004-01-12 Kompozycja do donosowego podawania fentanylu, zastosowanie farmaceutycznie dopuszczalnej substancji pomocniczej oraz sposób wytwarzania kompozycji

Country Status (26)

Country Link
US (5) US20040166067A1 (pl)
EP (2) EP2436375B1 (pl)
JP (1) JP4827725B2 (pl)
KR (3) KR20100118144A (pl)
CN (1) CN100423709C (pl)
AU (1) AU2004204381B2 (pl)
BR (1) BRPI0406674B8 (pl)
CA (1) CA2511974C (pl)
CY (1) CY1115056T1 (pl)
DK (1) DK1635783T5 (pl)
EA (1) EA008500B1 (pl)
ES (2) ES2432119T3 (pl)
FR (1) FR14C0020I1 (pl)
GB (1) GB0300531D0 (pl)
GE (1) GEP20084340B (pl)
HK (1) HK1088555A1 (pl)
IL (1) IL169480A (pl)
MX (1) MXPA05007333A (pl)
NO (1) NO335127B1 (pl)
NZ (1) NZ541018A (pl)
PL (1) PL212950B1 (pl)
PT (2) PT1635783E (pl)
SI (1) SI1635783T1 (pl)
UA (1) UA85050C2 (pl)
WO (1) WO2004062561A2 (pl)
ZA (1) ZA200505274B (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001281746C1 (en) * 2000-07-31 2010-09-09 ISTITUTO GENTILI S.r.l. Fentanyl composition for nasal administration
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
US20050129679A1 (en) 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
EP2057982A1 (en) 2007-11-09 2009-05-13 Archimedes Development Limited Intranasal compositions
GB2464282A (en) * 2008-10-08 2010-04-14 Archimedes Dev Ltd A device for administering a dose of opioid analgesic
CZ302789B6 (cs) 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
CA2824385A1 (en) 2011-02-04 2012-08-09 Archimedes Development Limited Improved container
AR086391A1 (es) 2011-05-13 2013-12-11 Euro Celtique Sa Formas de dosificacion farmaceutica intranasales que comprenden naloxona
PL2903608T3 (pl) 2012-10-03 2019-12-31 Proponent Biotech Gmbh Kompozycja farmaceutyczna obejmująca kwas propionowy do stosowania w leczeniu infekcji wirusowych
UA125204C2 (uk) 2013-09-05 2022-02-02 Аб2 Біо Са Застосування il-18-зв'язувального білка (il-18bp) при запальних захворюваннях
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
MY194040A (en) 2015-03-05 2022-11-09 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
US9650338B1 (en) 2016-07-29 2017-05-16 VDM Biochemicals, Inc. Opioid antagonist compounds and methods of making and using
PT3568126T (pt) * 2017-01-11 2023-12-19 Torrent Pharmaceuticals Ltd Composição nasal de tapentadol
US11207309B2 (en) 2019-07-19 2021-12-28 Hikma Pharmaceuticals International Limited Ready-to-administer fentanyl formulations
US11160799B2 (en) * 2019-10-22 2021-11-02 Cessatech A/S Pediatric combination
EP4146174A1 (en) 2020-05-06 2023-03-15 AB2 Bio SA Il-18 binding protein (il-18bp) in respiratory diseases
GB202007404D0 (en) 2020-05-19 2020-07-01 Nasser Syed Muhammad Tahir Treatment for viral respiratory infections
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
WO2023067348A1 (en) 2021-10-21 2023-04-27 Biosirius Ltd Treatment for virally-induced pneumonia
WO2023166206A1 (en) 2022-03-04 2023-09-07 Ab2 Bio Sa Il-18 binding protein (il-18bp) in the treatment of vexas

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2125212A (en) * 1938-05-03 1938-07-26 Vick Chemical Company Therapeutic composition
US2730483A (en) * 1952-08-12 1956-01-10 Nepera Chemical Co Inc Therapeutic compositions comprising neomycin, gramicidin and quaternary ammonium salt of thonzylamine
NL135583C (pl) * 1961-10-10
US3184600A (en) 1963-05-07 1965-05-18 Potter Instrument Co Inc Photosensitive apparatus for measuring coordinate distances
JPS5885813A (ja) * 1981-11-17 1983-05-23 Toyo Jozo Co Ltd 吸収性良好な製剤
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US4486423A (en) * 1983-04-21 1984-12-04 Janssen Pharmaceutica Inc. Stable fentanyl composition
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5122127A (en) 1985-05-01 1992-06-16 University Of Utah Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
HU193780B (en) * 1985-06-21 1987-11-30 Richter Gedeon Vegyeszet Process for producing 2-halogeno-6-methyl-ergol-9-ene derivatives and acid additional salts thereof
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JPS62123112A (ja) * 1985-11-22 1987-06-04 Sunstar Inc 軟膏基剤
DE3601132A1 (de) 1986-01-16 1987-07-23 Christian Bannert Verfahren zur behandlung der schleimhaut
JPS62236862A (ja) 1986-04-09 1987-10-16 Nippon Kayaku Co Ltd 人工粘液
ZA875317B (en) 1986-08-01 1988-01-25 Warner-Lambert Company Transdermal compositions
ES2042527T3 (es) 1986-11-14 1993-12-16 Theratech Inc Un metodo para preparar una composicion farmaceutica aumentadora de la penetracion para la aplicacion topica.
US4826683A (en) * 1987-01-09 1989-05-02 Bates Harry L Decongestant
US5200180A (en) * 1987-06-26 1993-04-06 Christian Bannert Pharmaceutical composition for the treatment of the human eye
DE3726797A1 (de) * 1987-08-12 1989-02-23 Bayer Ag Arzneimittel fuer den bereich der mundhoehle
US4915948A (en) 1987-08-31 1990-04-10 Warner-Lambert Company Tablets having improved bioadhesion to mucous membranes
US5457093A (en) * 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
DE3827561C1 (pl) * 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
GB8900267D0 (en) 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
GB8904370D0 (en) 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
JP2911496B2 (ja) * 1989-09-11 1999-06-23 帝國製薬株式会社 生理活性ポリペプチド含有高吸収性経膣剤
GB2237510B (en) 1989-11-04 1993-09-15 Danbiosyst Uk Small particle drug compositions for nasal administration
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
NL9000634A (nl) 1990-03-20 1991-10-16 Catharina Ziekenhuis Stichting Suspensie-injectiepreparaat op waterbasis, werkwijze voor de bereiding daarvan en toepassing van dit preparaat voor pijnbestrijding.
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
US5346703A (en) * 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
EP0491076A1 (en) 1990-12-19 1992-06-24 Theratech, Inc. Penetration enhancement with multi-component system of N-aliphatic pyrrolidones with lower alcohols
JPH0597706A (ja) 1991-04-09 1993-04-20 Chemex Block Drug Jv アフタ性潰瘍および他の粘膜皮膚障害の処置方法
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
ATE158172T1 (de) 1992-05-26 1997-10-15 Procter & Gamble Pulverförmige pharmazeutische zusammensetzung
DE69332378T2 (de) 1992-07-23 2003-07-10 Hisamitsu Pharmaceutical Co., Inc. Perkutan verabreichbare basiszusammensetzung und daraus hergestellte zusammensetzung
AU5551394A (en) 1992-11-09 1994-06-08 Pharmetrix Corporation Combined analgesic delivery methods for pain management
US5507277A (en) * 1993-01-29 1996-04-16 Aradigm Corporation Lockout device for controlled release of drug from patient-activateddispenser
ATE290864T1 (de) 1993-03-26 2005-04-15 Franciscus Wilhelmus He Merkus Pharmazeutische zusammensetzungen zur intranasalen verabreichung von dihydroergotamin
GB9310412D0 (en) 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
SE9301877D0 (sv) 1993-06-02 1993-06-02 Kabi Pharmacia Ab In situ gel for therapeutic use
BR9407397A (pt) 1993-07-12 1996-11-05 Virus Res Inst Vacinas microencapsuladas em hidrogel
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US5543434A (en) * 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
GB9406171D0 (en) * 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
EP0752855B1 (en) * 1994-03-30 1999-06-09 Gs Development Ab Use of fatty acid esters as bioadhesive substances
JP3483148B2 (ja) 1994-04-21 2004-01-06 久光製薬株式会社 経皮投与基剤組成物およびその薬剤組成物
AU700162B2 (en) * 1994-05-13 1998-12-24 Aradigm Corporation Narcotic containing aerosol formulation
GB9414966D0 (en) 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
FR2733420B1 (fr) 1995-04-28 1997-06-27 Sep Tarral Preparations pectiques utilisables comme support de medicament
ZA964320B (en) 1995-06-05 1997-01-13 Alza Corp Device for transdermal electrotransport delivery of fentanyl and sufentanil
CA2218369C (en) 1995-06-05 2010-02-09 Alza Corporation Transdermal electrotransport delivery of fentanyl and sufentanil
US6881208B1 (en) 1995-06-05 2005-04-19 Joseph B. Phipps Method and device for transdermal electrotransport delivery of fentanyl and sufentanil
JP3098401B2 (ja) 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
DE19527411A1 (de) * 1995-07-27 1997-01-30 Ackermann & Schmitt Gmbh & Co Kupplung
US5840731A (en) 1995-08-02 1998-11-24 Virginia Commonwealth University Pain-alleviating drug composition and method for alleviating pain
BR9710241A (pt) 1996-07-11 1999-08-10 Farmarc Nederland Bv Comprexo de inclusao que contem agonista de serotonina seletivo a indol
US6667279B1 (en) 1996-11-13 2003-12-23 Wallace, Inc. Method and composition for forming water impermeable barrier
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
GB2328443B (en) 1997-08-21 2001-09-05 Reckitt & Colmann Prod Ltd In situ formation of pharmaceutically acceptable polymeric material
RS49982B (sr) 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
DK1035833T3 (da) 1997-12-02 2006-01-09 Archimedes Dev Ltd Sammensætning til nasal indgivelse
US6090368A (en) 1998-03-03 2000-07-18 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
AU5305899A (en) 1998-08-26 2000-03-21 Teijin Limited Powdery pernasal compositions
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
GB9823246D0 (en) 1998-10-24 1998-12-16 Danbiosyst Uk A nasal drug delivery composition
JP2000229859A (ja) 1999-02-12 2000-08-22 Teijin Ltd 安定なブプレノルフィン経鼻製剤
AU2879100A (en) 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
JP2001002589A (ja) 1999-06-18 2001-01-09 Teijin Ltd 穏やかな薬物血中濃度の上昇を可能とする経鼻投与用組成物
ATE463259T1 (de) * 1999-08-26 2010-04-15 Takeda Pharmaceutical Nasenschleimhaut haftende matrix
JP2001089359A (ja) 1999-09-24 2001-04-03 Toko Yakuhin Kogyo Kk 鎮痛成分の点鼻用ゲルまたはゾル製剤
GB9924797D0 (en) * 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
AR031682A1 (es) 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
GEP20053614B (en) 2000-02-08 2005-09-26 Euro Celtique Sa Compositions for Oral Administration Containing Opioid Agonist
CA2402865A1 (en) 2000-03-10 2001-09-20 Durect Corporation Opioid formulations
US6610271B2 (en) 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
AU2001262992A1 (en) 2000-05-10 2002-02-18 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
US20030190290A1 (en) 2000-06-22 2003-10-09 Calvin Ross Pharmaceutical compositions
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
AU2001281746C1 (en) * 2000-07-31 2010-09-09 ISTITUTO GENTILI S.r.l. Fentanyl composition for nasal administration
DE10064219B9 (de) 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
US6777000B2 (en) 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
GB2378383A (en) 2001-06-06 2003-02-12 Gursharan Moonga Nasal delivery of pharmaceutical compositions in powder form
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
JP2006516272A (ja) 2006-06-29
JP4827725B2 (ja) 2011-11-30
ES2432119T3 (es) 2013-11-29
KR20100118144A (ko) 2010-11-04
PT2436375T (pt) 2019-05-24
CA2511974A1 (en) 2004-07-29
BRPI0406674B8 (pt) 2021-05-25
CN1723012A (zh) 2006-01-18
UA85050C2 (ru) 2008-12-25
KR20090058596A (ko) 2009-06-09
GEP20084340B (en) 2008-03-25
US20040166067A1 (en) 2004-08-26
ES2721899T3 (es) 2019-08-06
EP2436375B1 (en) 2019-02-27
US8216604B2 (en) 2012-07-10
IL169480A (en) 2013-10-31
CY1115056T1 (el) 2016-12-14
BRPI0406674B1 (pt) 2015-12-22
WO2004062561A2 (en) 2004-07-29
EA200501105A1 (ru) 2005-12-29
KR101012148B1 (ko) 2011-02-07
AU2004204381A1 (en) 2004-07-29
GB0300531D0 (en) 2003-02-12
EP2436375A1 (en) 2012-04-04
AU2004204381B2 (en) 2010-11-25
CA2511974C (en) 2011-03-01
PT1635783E (pt) 2013-10-29
US20150283123A1 (en) 2015-10-08
EP1635783B1 (en) 2013-09-18
DK1635783T3 (da) 2013-10-14
KR20050103275A (ko) 2005-10-28
MXPA05007333A (es) 2006-02-17
US8889176B2 (en) 2014-11-18
NZ541018A (en) 2008-07-31
CN100423709C (zh) 2008-10-08
EA008500B1 (ru) 2007-06-29
SI1635783T1 (sl) 2013-11-29
NO335127B1 (no) 2014-09-22
PL212950B1 (pl) 2012-12-31
US20080153879A1 (en) 2008-06-26
ZA200505274B (en) 2014-09-25
HK1088555A1 (en) 2006-11-10
NO20053119L (no) 2005-08-03
US9078814B2 (en) 2015-07-14
BRPI0406674A (pt) 2005-12-20
NO20053119D0 (no) 2005-06-24
US20120277267A1 (en) 2012-11-01
FR14C0020I1 (fr) 2014-04-18
US9814705B2 (en) 2017-11-14
EP1635783A2 (en) 2006-03-22
US20120270903A1 (en) 2012-10-25
AU2004204381A2 (en) 2004-07-29
IL169480A0 (en) 2007-07-04
DK1635783T5 (da) 2014-05-12
WO2004062561A3 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
GB0320382D0 (en) Pharmaceutical compositions
GB0327723D0 (en) Pharmaceutical compositions
GB2389530B (en) Pharmaceutical compositions
EP1765283A4 (en) PHARMACEUTICAL COMPOSITIONS
ZA200605080B (en) Pharmaceutical compositions
GB2391473B (en) Pharmaceutical compositions
HU0301154D0 (en) Pharmaceutical composition
GB0300531D0 (en) Pharmaceutical compositions
GB0300427D0 (en) Pharmaceutical composition
HK1084670A1 (en) Pharmaceutical compositions comprising cabbinochreme type compounds
EP1648411A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0307866D0 (en) Pharmaceutical composition
EP1805154A4 (en) PHARMACEUTICAL COMPOSITIONS
EP1699458A4 (en) PHARMACEUTICAL COMPOSITION
GB0329232D0 (en) Pharmaceutical composition
GB0317663D0 (en) Pharmaceutical composition
HK1093896A1 (en) Medicinal composition
HU0302441D0 (en) Pharmaceutical compositions having antibiothic effect
GB0300885D0 (en) Pharmaceutical composition
EP1655029A4 (en) MEDICINAL COMPOSITIONS
GB0213481D0 (en) Pharmaceutical compositions
EP1600445A4 (en) CURATIVE PREPARATION
EP1480649A4 (en) STABLE PHARMACEUTICAL COMPOSITIONS
GB0306933D0 (en) Pharmaceutical composition
GB0305579D0 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
RECP Rectifications of patent specification